AstraZeneca, GB0009895292

AstraZeneca stock falls 2.65 percent after the close

Published on 09/23/2026 at 22:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 23, 2026, AstraZeneca stock had fallen 2.65 percent on the Nasdaq to USD 168.37, while the Nasdaq Composite was down 1.08 percent. Trixeo EU approval and the next results date remain in view.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor
AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca stock closed at USD 168.37 on the Nasdaq on September 23, 2026, down 2.65 percent from the prior close. The Nasdaq Composite fell 1.08 percent to 27,244.28, putting the ADR 1.57 percentage points below the broad technology-heavy market measure.

September 23, 2026 in numbers

AstraZeneca PLC (ISIN GB0009895292) opened at USD 168.29 and reached USD 168.37 during the session, according to the session quote. The ADR therefore finished USD 0.08 above its reported opening level while remaining below the previous close.

In London, AstraZeneca shares closed 1.91 percent lower at 11:35 a.m. ET, while Reuters reported that pharmaceutical stocks were the largest drag on the FTSE indexes. MarketScreener listed European approval of Trixeo and scheduled AstraZeneca's third-quarter 2026 results for October 30.

Results due on October 30

AstraZeneca's next scheduled quarterly results are due on October 30, 2026, according to MarketScreener. The European regulatory approval for Trixeo was also reported on September 23, 2026, keeping the company event in the session's news flow.

Disclaimer...

en | GB0009895292 | ASTRAZENECA | boerse | 70170404 | bgmi